Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Trial of sEphB4-HSA in Combination With Anti PD-1 Antibody (Pembrolizumab, MK3475) in Patients With Non-small Cell Lung and Head/Neck Cancer

NCT03049618 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT03049618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03049618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Trial of sEphB4-HSA in Combination With Anti PD-1 Antibody (Pembrolizumab, MK3475) in Patients With Non-small Cell Lung and Head/Neck Cancer
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Completed
Start date
March 10, 2017
Completion date
September 4, 2024
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk gene mutation, braf gene mutation, egfr gene mutation, head and neck squamous cell carcinoma, metastatic head and neck carcinoma, recurrent head and neck carcinoma, recurrent non-small cell lung carcinoma, ros1 gene mutation, stage iii non-small cell lung cancer, stage iiia non-small cell lung cancer, stage iiib non-small cell lung cancer, stage iv non-small cell lung cancer